APOTEX-RAMIPRIL ramipril 1.25mg capsule bottle

Nchi: Australia

Lugha: Kiingereza

Chanzo: Department of Health (Therapeutic Goods Administration)

Viambatanisho vya kazi:

ramipril, Quantity: 1.25 mg

Inapatikana kutoka:

Arrotex Pharmaceuticals Pty Ltd

INN (Jina la Kimataifa):

Ramipril

Dawa fomu:

Capsule

Tungo:

Excipient Ingredients: lactose monohydrate; iron oxide yellow; Gelatin; magnesium stearate; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; Shellac; sulfuric acid

Njia ya uendeshaji:

Oral

Vitengo katika mfuko:

30

Dawa ya aina:

(S4) Prescription Only Medicine

Matibabu dalili:

? Treatment of hypertension. (Data are currently not available to support the use of ramipril in renovascular hypertension).,? Post MI heart failure.,? Prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day.,? For reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease.,? For reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mm Hg or diastolic blood pressure > 90 mm Hg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/L; HDL cholesterol < 0.9 mmol/L; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Bidhaa muhtasari:

Visual Identification: yellow cap & white body imprinted with APO 1.25 in black ink; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Idhini hali ya:

Licence status A

Idhini ya tarehe:

2011-09-27